Nabsys is dedicated to enabling advances in life sciences and healthcare through strategic deployment of a novel positional sequencing platform with broad applicability for DNA analysis. The Nabsys platform uses solid-state nanodetectors to analyze single DNA molecules, revealing both location and identity of DNA sequences over long distances. The system is designed to set new standards for accuracy, speed and scalability, offering compelling advantages for the analysis of genome structural variation, genome mapping, and both targeted and whole genome sequencing.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
03/13/13 | $20,000,000 | Series D |
Point Judith Capital | undisclosed |
03/13/13 | $20,000,000 | Series D |